Further validation in larger, independent cohorts, as well as longitudinal studies, is needed to establish IFN-α and IFN-γ as routine biomarkers for disease monitoring and to refine therapeutic strategies, particularly in DM. The gene discussed is IFNA1; the disease is dermatomyositis.